A deal? An asset sale? A launch? Everyone is watching next moves for Roivant, BridgeBio
What’s next for two of biotech’s once-cool, now-hot companies?
Hot on the heels of critical data readouts, Roivant Sciences and BridgeBio Pharma are enjoying two of 2023’s most dramatic stock turnarounds, after their briefly-out-of-favor business models have turned up potential blockbuster drugs.
Successful readouts of the programs — Roivant’s stomach drug, RVT-3101, and BridgeBio’s heart pill, acoramidis — have prompted the sort of question that faces any smaller company after positive data. In Roivant’s case, there have been reports that it plans to sell the drug for as much as $7 billion — but no deal has materialized. And BridgeBio was said to have attracted inquiries from larger drugmakers ahead of its readout, but the company hasn’t announced a deal or its own financing plans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.